Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV002446951 | SCV002612496 | likely pathogenic | Cardiovascular phenotype | 2019-03-25 | criteria provided, single submitter | clinical testing | The p.G109D variant (also known as c.326G>A), located in coding exon 8 of the COL1A2 gene, results from a G to A substitution at nucleotide position 326. The glycine at codon 109 is replaced by aspartic acid, an amino acid with similar properties. The majority of pathogenic mutations identified to date in COL1A2 have involved the substitution of another amino acid for glycine within the triple-helical domain (Dagleish R. Nucleic Acids Res. 1997 Jan 1;25(1):181-7; Marini JC et al. Hum Mutat. 2007 Mar;28(3):209-21; Bardai G et al. Osteoporos Int 2016 Dec;27(12):3607-3613). This particular glycine substitution has been reported in several patients with osteogenesis imperfecta and Ehlers-Danlos overlap syndrome (Malfait F et al. Orphanet J Rare Dis, 2013 May;8:78; Malmgren B et al. Oral Dis, 2017 Jan;23:42-49). Functional studies in patient fibroblasts suggest that this alteration results in delayed processing of procollagen I into the mature protein (Malfait F et al. Orphanet J Rare Dis, 2013 May;8:78). Internal structural analysis indicates that this alteration disrupts the characteristic G-X-Y motif in the COL1A2 protein and inserts a bulky side chain into a sterically-constrained region (Bella J et al. Science. 1994;266:75-81; Hohenester E et al. Proc. Natl. Acad. Sci. U.S.A. 2008;105:18273-7; Ambry internal data). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. |
| Department of Medical Sciences, |
RCV000490674 | SCV000574661 | pathogenic | Osteogenesis imperfecta type I | no assertion criteria provided | clinical testing | ||
| OMIM | RCV001270303 | SCV001450511 | pathogenic | Combined osteogenesis imperfecta and Ehlers-Danlos syndrome 2 | 2021-07-29 | no assertion criteria provided | literature only |